多重耐药鲍曼不动杆菌耐药机制及治疗策略的研究进展(4)
第1页 |
参见附件。
[18] Sader HS,Jones RN,Dowzicky M J,et al.Antimicrobial activity oftigecycline tested against nosocomial bacterial pathogens from patientshospitalized in the intensive care unit[J].Diagn Microbiol Infect Dis,2005,52(2):203-208.
[19] 陈月馨,张宇锋,席云,等.多耐药鲍氏不动杆菌对替加环素的耐药分析[J].热带医学杂志,2010,10(11): 1316-1318.
[20] Taccone FS,Rodriguez-Villalobos H,De Backer D,et al.Successfultreatment of septic shock due to pan-resistant Acinetobacter baumanniiusing combined anti-microbial therapy including tigecycline[J]. Eur J Clin Microbiol Infect Dis,2006,25(4):257-260.
[21] Sobieszczyk ME,Furuya EY,Hay CM,et al.Combination therapy withpoly-myxin B for the treatment of multidrug-resistant Gram-negativerespiratory tract infections[J].J Antimicrob Chemother,2004,54(2):566-569.
[22] 杨莉,韩立中,孙景勇,等.多重耐药鲍曼不动杆菌中仅黏菌素敏感菌株的分子流行病学研究[J].中华医学杂志, 2006,86(9):592-595.
[23] Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity ofintravenous colistin: a prospective evaluation[J]. Int J Antimicrob Agents,2005,26(6):504-507.
[24] 陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85.
[25] Garcia-Quintanilla M,Pulido MR,Lopez-Rojas R.Emerging therapies for multidrug resistant Acinetobacter baumannii[J].Trends Microbiol,2013,21(3):157-163.
(收稿日期:2014-04-08)
您现在查看是摘要介绍页,详见PDF附件。